| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802588701038 | 258870103 | NEULASTA INJ.SOL 6MG/0,6ML(10MG/ML) PF.SYR BTx1PF.SYR.x0,6ML με μηχανισμό κάλυψης βελόνας με μηχανισμό κάλυψης βελόνας | 642.86 | 652.50 | 740.07 |
Increases leukocyte production, for treatment in non-myeloid cancer,neutropenia and bone marrow transplant
Filgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase
* 150 mL/kg [normal subjects and cancer patients]
* 0.5 - 0.7 mL/minute/kg [SC administration of 3.45 mcg/kg and 11.5 mcg/kg in both normal subjects and cancer patients]
Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant
Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase
15-80 hrs